Patient Leaflet Updated 06-Jul-2023 | Krka UK Ltd
Ranolazine Krka 375 mg prolonged-release tablets
Ranolazine Krka 375 mg prolonged-release tablets
Ranolazine Krka 500 mg prolonged-release tablets
Ranolazine Krka 750 mg prolonged-release tablets
ranolazine
1. What Ranolazine Krka is and what it is used for
2. What you need to know before you take Ranolazine Krka
3. How to take Ranolazine Krka
4. Possible side effects
5. How to store Ranolazine Krka
6. Contents of the pack and other information
Ranolazine Krka is a medicine used in combination with other medicines to treat angina pectoris, which is a chest pain or discomfort that you feel anywhere along the upper part of your body between your neck and upper abdomen, often brought on by exercise or too much activity.
You must talk to a doctor if you do not feel better or if you feel worse.
Talk to your doctor or pharmacist before taking Ranolazine Krka.
Your doctor may decide to give you a lower dose or take other precautions if any of these apply to you.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Do not use the following medicines if you take Ranolazine Krka:
Tell your doctor or pharmacist before you take Ranolazine Krka if you use:
Ranolazine Krka can be taken with or without food. While being treated with Ranolazine Krka, you should not drink grapefruit juice.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
You should not take Ranolazine Krka if you are pregnant unless your doctor has advised you to do so.
Breast-feeding
You should not take Ranolazine Krka if you are breast-feeding. Ask your doctor for advice if you are breastfeeding.
No studies on the effects of Ranolazine Krka on the ability to drive and use machines have been performed. Ask your doctor for advice about driving or using machines.
Ranolazine Krka may cause side effects such as dizziness (common), blurred vision (uncommon), confusional state (uncommon), hallucination (uncommon), double vision (uncommon), coordination problems (rare), that may affect your ability to drive or use machines. If you experience these symptoms, do not drive or operate machinery until they have resolved completely.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Always swallow the tablets whole with water. Do not crush, suck, or chew the tablets or break them in half, as this might affect the way the medicine is released from the tablets into your body.
The starting dose for adults is one 375 mg tablet twice a day. After 2−4 weeks, your doctor may increase the dose to get the right effect. The maximum dose of Ranolazine Krka is 750 mg twice a day.
It is important that you tell your doctor if you get side effects such as dizziness or feeling or being sick. Your doctor may lower your dose or, if this is not sufficient, stop treatment with Ranolazine Krka.
Children and adolescents under 18 years old should not take Ranolazine Krka.
If you accidentally take too many Ranolazine Krka tablets or take a higher dose than recommended by your doctor, it is important that you tell your doctor at once. If you cannot contact your doctor, go to the nearest accident and emergency department. Take along any tablets that are left, including the container and the carton, so that the hospital staff can easily tell what you have taken.
If you forget to take a dose, take it as soon as you remember unless it is nearly time (less than 6 hours) to take your next dose. Do not take a double dose to make up for a forgotten dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should stop taking Ranolazine Krka and see your doctor immediately if you experience the following symptoms of angioedema, which is a rare condition but can be severe:
Tell your doctor if you experience common side effects such as dizziness or feeling sick or vomiting. Your doctor may lower your dose or stop treatment with Ranolazine Krka.
Other side effects, you may experience include the following:
Common side effects (may affect up to 1 in 10 people) are:
Uncommon side effects (may affect up to 1 in 100 people) are:
Rare side effects (may affect up to 1 in 1 000 people) are:
Not known side effects (frequency cannot be estimated from the available data) are:
If you get any side effects, talk to your doctor or pharmacist or nure. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month.
Store below 25 °C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
See section 2 “Ranolazine Krka contains sodium”.
Ranolazine Krka 375 mg prolonged-release tablets:
Prolonged-release tablets are white, oval, biconvex, film-coated, marked with 375 on one side of the tablet. Tablet dimensions: approximately 15 × 7 mm.
Ranolazine Krka 500 mg prolonged-release tablets:
Prolonged-release tablets are pale brownish yellow, oval, biconvex, film-coated, marked with 500 on one side of the tablet. Tablet dimensions: approximately 17 × 8 mm.
Ranolazine Krka 750 mg prolonged-release tablets:
Prolonged-release tablets are pink, oval, biconvex, film-coated, marked with 750 on one side of the tablet. Tablet dimensions: approximately 19 × 9 mm.
Ranolazine Krka is available in packs containing 30, 60 and 100 prolonged-release tablets in blisters.
Not all pack sizes may be marketed.
This leaflet was last revised in United Kingdom (Northern Ireland) in 01/2023.
This leaflet was last revised in United Kingdom (Great Britain) in 02/2023.
KRKA UK Ltd, Thames House, Waterside Drive, Langley, Slough, SL3 6EZ, UK
+44 (0)7572 410 233
+44 (0)7894 980 624
www.krka.co.uk
+44 (0)207 164 6156